PubRank

Gordon S Lynch

Author PubWeight™ 79.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008 2.20
2 Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 2012 2.04
3 Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology 2008 1.67
4 Adipose triacylglycerol lipase deletion alters whole body energy metabolism and impairs exercise performance in mice. Am J Physiol Endocrinol Metab 2009 1.62
5 Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002 1.48
6 Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 2008 1.46
7 The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 2008 1.38
8 Whole body deletion of AMP-activated protein kinase {beta}2 reduces muscle AMPK activity and exercise capacity. J Biol Chem 2010 1.30
9 Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 2003 1.25
10 AMPK-independent pathways regulate skeletal muscle fatty acid oxidation. J Physiol 2008 1.23
11 The orphan nuclear receptor, NOR-1, is a target of beta-adrenergic signaling in skeletal muscle. Endocrinology 2006 1.21
12 Evaluating an internet weight loss program for diabetes prevention. Health Promot Int 2005 1.21
13 Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes 2012 1.20
14 Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 2010 1.19
15 Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 2006 1.17
16 Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul Disord 2006 1.16
17 Skeletal muscle glucose uptake during contraction is regulated by nitric oxide and ROS independently of AMPK. Am J Physiol Endocrinol Metab 2009 1.16
18 Elevated expression of activins promotes muscle wasting and cachexia. FASEB J 2013 1.13
19 Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic {beta}-adrenoceptor stimulation in mice. J Physiol 2010 1.11
20 Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005 1.10
21 Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function. Mol Ther 2005 1.10
22 Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol 2011 1.08
23 Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J Physiol 2006 1.08
24 Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice. Am J Physiol Endocrinol Metab 2006 1.08
25 Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech 2012 1.08
26 Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 2002 1.06
27 Notexin causes greater myotoxic damage and slower functional repair in mouse skeletal muscles than bupivacaine. Muscle Nerve 2006 1.04
28 Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. Am J Pathol 2009 1.03
29 The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol 2004 1.03
30 Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am J Physiol Endocrinol Metab 2006 1.02
31 Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 2007 0.98
32 Length-tension relationships are altered in regenerating muscles of the rat after bupivacaine injection. J Appl Physiol (1985) 2005 0.98
33 Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004 0.97
34 Cytoskeletal tropomyosin Tm5NM1 is required for normal excitation-contraction coupling in skeletal muscle. Mol Biol Cell 2008 0.96
35 Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 2007 0.95
36 Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2009 0.94
37 Expression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 2009 0.94
38 Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 2010 0.94
39 Beta2-agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle. Am J Physiol Endocrinol Metab 2004 0.93
40 Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity. Am J Physiol Heart Circ Physiol 2008 0.92
41 Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol (1985) 2003 0.91
42 Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J Biol Chem 2011 0.90
43 The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol Ther 2008 0.90
44 Plasmid-based gene transfer in mouse skeletal muscle by electroporation. Methods Mol Biol 2008 0.89
45 Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice. Int J Cardiol 2010 0.89
46 Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction. Am J Physiol Regul Integr Comp Physiol 2009 0.89
47 Excitation-contraction coupling and sarcoplasmic reticulum function in mechanically skinned fibres from fast skeletal muscles of aged mice. J Physiol 2002 0.87
48 Differential calcineurin signalling activity and regeneration efficacy in diaphragm and limb muscles of dystrophic mdx mice. Neuromuscul Disord 2006 0.87
49 Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol 2008 0.87
50 Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. J Muscle Res Cell Motil 2003 0.86
51 Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. J Appl Physiol (1985) 2011 0.86
52 Hydrogen peroxide increases depolarization-induced contraction of mechanically skinned slow twitch fibres from rat skeletal muscles. J Physiol 2002 0.86
53 Depolarization-induced contraction and SR function in mechanically skinned muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 2003 0.86
54 Stimulation of calcineurin Aalpha activity attenuates muscle pathophysiology in mdx dystrophic mice. Am J Physiol Regul Integr Comp Physiol 2008 0.85
55 Changes in contractile activation characteristics of rat fast and slow skeletal muscle fibres during regeneration. J Physiol 2004 0.85
56 Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. Am J Physiol Heart Circ Physiol 2005 0.84
57 Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy. Exp Physiol 2014 0.84
58 beta-Adrenoceptor signaling in regenerating skeletal muscle after beta-agonist administration. Am J Physiol Endocrinol Metab 2007 0.84
59 Calcineurin-A alpha activation enhances the structure and function of regenerating muscles after myotoxic injury. Am J Physiol Regul Integr Comp Physiol 2007 0.84
60 Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia. Int J Cancer 2013 0.83
61 Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 2007 0.83
62 Early functional muscle regeneration after myotoxic injury in mice is unaffected by nNOS absence. Am J Physiol Regul Integr Comp Physiol 2011 0.83
63 Ageing prolongs inflammatory marker expression in regenerating rat skeletal muscles after injury. J Inflamm (Lond) 2011 0.82
64 Leucine as a treatment for muscle wasting: a critical review. Clin Nutr 2014 0.81
65 Disruption of muscle renin-angiotensin system in AT1a-/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury. Am J Physiol Regul Integr Comp Physiol 2012 0.81
66 Editorial update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2012 0.80
67 Novel role for ß-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin Exp Pharmacol Physiol 2009 0.80
68 Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. J Appl Physiol (1985) 2008 0.80
69 Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. Hum Mol Genet 2013 0.79
70 Amino acid sensing and activation of mechanistic target of rapamycin complex 1: implications for skeletal muscle. Curr Opin Clin Nutr Metab Care 2016 0.79
71 Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. Med Sci Sports Exerc 2002 0.79
72 Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Horm IGF Res 2012 0.79
73 Intramuscular administration of PEGylated IGF-I improves skeletal muscle regeneration after myotoxic injury. Growth Horm IGF Res 2013 0.78
74 Downstream mechanisms of nitric oxide-mediated skeletal muscle glucose uptake during contraction. Am J Physiol Regul Integr Comp Physiol 2010 0.78
75 Disease-Induced Skeletal Muscle Atrophy and Fatigue. Med Sci Sports Exerc 2016 0.77
76 Physiological characterization of a mouse model of cachexia in colorectal liver metastases. Am J Physiol Regul Integr Comp Physiol 2013 0.77
77 Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol. Muscle Nerve 2002 0.77
78 Emerging drugs for treating skeletal muscle injury and promoting muscle repair. Expert Opin Emerg Drugs 2011 0.77
79 Arginine protects muscle cells from wasting in vitro in an mTORC1-dependent and NO-independent manner. Amino Acids 2014 0.76
80 Parvalbumin gene transfer impairs skeletal muscle contractility in old mice. Hum Gene Ther 2012 0.75
81 Skeletal effects of the alteration of masseter muscle function. Aust Orthod J 2015 0.75
82 Glycine metabolism in skeletal muscle: implications for metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2017 0.75
83 Endurance training adaptations modulate the redox-force relationship of rat isolated slow-twitch skeletal muscles. Clin Exp Pharmacol Physiol 2003 0.75
84 The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders. Curr Opin Clin Nutr Metab Care 2009 0.75